Chengdu Mizi Biopharmaceutical Technology

Chengdu Mizi Biopharmaceutical Technology is a clinical-stage biotechnology company based in Chengdu, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-value targets within the ubiquitin-proteasome system, particularly ubiquitin-specific proteases (USPs), to address unmet needs in oncology. Its lead candidate, MZ-001, is a potent and selective USP1 inhibitor currently in Phase 1 clinical trials for the treatment of advanced solid tumors with homologous recombination deficiency (HRD). Mizi Biopharmaceutical leverages its proprietary drug discovery platform to rapidly advance a pipeline of precision medicines from early discovery through clinical proof-of-concept.